Arkolith/Insider Trading/RAPH/Form 4

Louria Hayon Igal

Chief Technology OfficerRaphael Pharmaceutical Inc. (RAPH) · full profile →Form 4 · filed Apr 6, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 20, 2025Option exercise(X)350K$0.01$4K1.3M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Nov 20, 2025Option exercise(X)350K——0

Transaction Codes

X
Exercise of in-the-money derivative

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001213900-26-040590) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML